Type 1 diabetes (T1D) is a chronic disease, characterized by absent or near absent beta-cell function, that requires insulin therapy.1 Patients with T1D are often treated with a regimen of multiple daily injections (MDI), comprising a long-acting basal component and a mealtime bolus component of short-acting insulin.1 The development of faster-acting insulin analogs for prandial dosing increases the treatment options for patients, potentially offering improved glycemic control and more flexibility with dose timing.1–5. Here, INS is linked to type 1 diabetes mellitus.